Abstract
Membranous nephropathy is a common cause of primary nephrotic syndrome, yet it can be particularly vexing to treat due to its extended duration and uncertainties about the implications of a partial remission. Ten years ago, the phospholipase A2 receptor (PLA2R) was identified as the major target
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Clinical journal of the American Society of Nephrology : CJASN
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.